Traditional Chinese medicine herbal treatment may have a relevant impact on the prognosis of patients with stage IV adenocarcinoma of the lung treated with platinum-based chemotherapy or combined targeted therapy and chemotherapy

Integrative Cancer Therapies

Volumn 10, Issue 2, 2011, Pages 127-137

  Guo, Huiru ^a   Liu, Jia Xiang ^a   Xu, Ling ^a   Madebo, Tesfaye ^b   Baak, Jan P A ^b,c  

^a LONGHUA HOSPITAL AFFILIATED TO SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b STAVANGER UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF BERGEN   (Norway)

Author keywords

chemotherapy; prognosis; pulmonary adenocarcinoma; stage IV; targeted therapy; TCM herbal treatment

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED; PLATINUM; PLATINUM BASED ANTINEOPLASTIC AGENT; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHINESE MEDICINE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG TARGETING; FEMALE; FOLLOW UP; HERBAL MEDICINE; HUMAN; KAPLAN MEIER METHOD; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICINAL PLANT; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; SYNDROME; TRADITIONAL CHINESE MEDICINE SYNDROME; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CISPLATIN; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DRUG THERAPY, COMBINATION; DRUGS, CHINESE HERBAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MEDICINE, CHINESE TRADITIONAL; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; OUTPATIENTS; PACLITAXEL; PLATINUM COMPOUNDS; PROGNOSIS; QUINAZOLINES; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME; VINBLASTINE;

EID: 79959801410     PISSN: 15347354     EISSN: 1552695X     Source Type: Journal    
DOI: 10.1177/1534735410387599     Document Type: Article

References (41)

1. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359:1367-1380.
2. Ministry of Health, China. http://www.moh.gov.cn/publicfiles/business/ htmlfiles/zwgkzt/ptjnj/year2009/t-9.htm. Accessed August 26, 2009.
3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-249.
4. Stabile LP, Lyker JS, Gubish CT, Zhang W, Grandis JR, Siegfried JM. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res. 2005;65:1459-1470. (Pubitemid 40270175)
5. Zhao YY, Zhang Y, Zhao HY, et al. Predictive factors for response and survival of gefitinib-treated locally advanced or metastatic non-small cell lung cancer patients: a retrospective analysis of two phase II clinical trials [in Chinese]. Ai Zheng. 2009;28:626-631.
6. Gazdar AF. Personalized medicine and inhibition of EGFR signaling in lung cancer. N Engl J Med. 2009;361: 1018-1020.
7. Green MR. Targeting targeted therapy. N Engl J Med. 2004; 350:2191-2193. (Pubitemid 38638000)
8. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med. 2008;358:1160-1174.
9. McCulloch M, See C, Shu X, et al. Astragalus-based Chinese Herbs and platinum-based chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. J Clin Oncol. 2006;24:419-430. (Pubitemid 46655594)
10. Liu JX, Shi ZM, Li HG. The clinical research of the principle of nourishing yin and promoting fluid production, benefiting qi and warming yang in treating advanced primary lung adenocarcinoma. J Tradit Chin Med. 1995;36:155-158.
11. Mok TS, Wu Y-L, Thongprasert S, et al. Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947-957.
12. Schiller JH, Harrington D, Belani CP, et al; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92-98. (Pubitemid 34438899)
13. Lam YC, Cheng CW, Peng H, Law CK, Huang X, Bian Z. Cancer patients' attitudes towards Chinese medicine: a Hong Kong survey. Chin Med. 2009;4:25.
14. Ettinger DS, Akerley W, Bepler G, et al. NCCN Non-Small Cell Lung Cancer Panel Members. Non-small cell lung cancer. J Natl Compr Canc Netw. 2010;8(7):740-801.
15. Zheng XY. Guiding Principles for Clinical Research on New Drugs of Traditional Chinese Medicine (Trial Implementation). Beijing, China: China Medical-Pharmaceutical Science & Technology Publishing House; 2002.
16. Zhao SM. Invigorate deficiency medicine. In: Chinese Materia Medica. Beijing, China: People's Medical Publishing House.
17. Lee JJ, Lee JJ. A phase II study of an herbal decoction that includes Astragali radix for cancer-associated anorexia in patients with advanced cancer. Integr Cancer Ther. 2010;9: 24-31.
18. Sheng R, Xu X, Tang Q, et al. Polysaccharide of Radix Pseudostellariae improves chronic fatigue syndrome induced by poly I:C in mice [published online ahead of print December 11, 2009]. Evid Based Complement Alternat Med. doi:10.1093/ecam/nep208.
19. Chen X, Zhang L, Cheung PC. Immunopotentiation and antitumor activity of carboxymethylated-sulfated beta-(1→3)-D-glucan from Poria cocos. Int Immunopharmacol. 2010; 10:398-405.
20. Wang Y, Dong H, Zhu M, et al. Icariin exterts negative effects on human gastric cancer cell invasion and migration by vasodilator-stimulated phosphoprotein via Rac1 pathway. Eur J Pharmacol. 2010;635:40-48.
21. Zhou L, Tang YP, Gao L, Fan XS, Liu CM, Wu DK. Separation, characterization and dose-effect relationship of the PPARgamma-activating bio-active constituents in the Chinese herb formulation "San-Ao decoction". Molecules. 2009; 14: 3942-3951.
22. Gautam M, Saha S, Bani S, et al. Immuno-modulatory activity of Asparagus racemosus on systemic Th1/Th2 immune: implications for immuno-adjuvant potential. J Ethnopharmacol. 2009;21:241-247.
23. Agrawal A, Sharma M, Rai SK, Singh B, Tiwari M, Chandra R. The effect of the aqueous extract of the roots of Asparagus racemosus on hepatocarcinogenesis initiated by diethylnitrosamine. Phytother Res. 2008;22:1175-1182.
24. Zhou L, Zhang Y, Gapter LA, Ling H, Agarwal R, Ng KY. Cytotoxic and anti-oxidant activities of lanostane-type triterpenes isolated from Poria cocos. Chem Pharm Bull. 2008;56: 1459-1462.
25. Wu X, Dai H, Huang L, Gao X, Tsim KW, Tu P. A fructan, from Radix ophiopogonis, stimulates the proliferation of cultured lymphocytes: structural and functional analyses. J Nat Prod. 2006;69:1257-1260. (Pubitemid 44568229)
26. Koo HN, Jeong HJ, Choi JY, et al. Inhibition of tumor necrosis factor-alpha-induced apoptosis by Asparagus cochinchinensis in Hep G2 cells. J Ethnopharmacol. 2000;73: 137-143.
27. Wang Y, Zhang Z, Garbow JR, et al. Chemoprevention of lung squamous cell carcinoma in mice by a mixture of Chinese herbs. Cancer Prev Res. 2009;2:634-640.
28. Engi H, Hohmann J, Gang G, et al. Chemoprevention and inhibition of P-glycoprotein in cancer cells by Chinese medicinal herbs. Phytother Res. 2008;22:1671-1676.
29. Wald M. Exogenous proteases confer a significant chemopreventive effect in experimental tumor models. Integr Cancer Ther. 2008;7:295-310.
30. Amirghofran Z, Bahmani M, Azadmehr A, Javidnia K. Induction of apoptosis in leukemia cell lines by Linum persicum and Euphorbia cheiradenia. J Cancer Res Clin Oncol. 2006;132:427-432.
31. Block KI, Mead MN. Immune system effects of echinacea, ginseng, and astragalus: a review. Integr Cancer Ther. 2003; 2:247-267. (Pubitemid 37138611)
32. Maione P, Perrone F, Gallo C, et al. Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the Multicenter Italian Lung Cancer in the Elderly Study. J Clin Oncol. 2005;23:6865-6872.
33. Movsas B, Moughan J, Sarna L, et al. Quality of life supersedes the classic prognosticators for long-term survival in locally advanced non-small-cell lung cancer: an analysis of RTOG 9801. J Clin Oncol. 2009;27:5816-5822.
34. Pirl WF, Temel JS, Billings A, et al. Depression after diagnosis of advanced non-small cell lung cancer and survival: a pilot study. Psychosomatics. 2008;49:218-224. (Pubitemid 351668723)
35. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363:733-742.
36. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003;290:2149-2158. (Pubitemid 37432975)
37. Pérez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol. 2004;22: 3238-3247. (Pubitemid 41103678)
38. Baak JP, Oort J. Reproducibility of diagnostic assessments. In: Baak JP, Oort J, eds. Manual of Quantitative Pathology in Cancer Diagnosis and Prognosis. New York, NY: Springer; 1991.
39. Bol MG, Baak JP, Buhr-Wildhagen S, et al. Reproducibility and prognostic variability of grade and lamina propria invasion in stages Ta, T1 urothelial carcinoma of the bladder. J Urol. 2003;169:1291-1294. (Pubitemid 36323769)
40. Baak JP, Langley FA, Talerman A, Delemarre JF. The prognostic variability of ovarian tumor grading by different pathologists. Gynecol Oncol. 1987;27:166-172. (Pubitemid 17065826)
41. Zhu WF, Yan JF, Huang BQ. Application of Bayesian network in syndrome differentiation system of traditional Chinese medicine [in Chinese]. Zhong Xi Yi Jie He Xue Bao. 2006;4:567-571.